Advertisement Teva introduces generic equivalent of Symbyax in US - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Teva introduces generic equivalent of Symbyax in US

Teva Pharmaceutical Industries has launched Olanzapine and Fluoxetine Capsules USP 6mg/25mg, 12mg/25mg, 6mg/50mg, and 12mg/50mg.

The Olanzapine and Fluoxetine Capsules are the company’s generic equivalent to Symbyax.

Lilly USA commercializes Symbyax, which is approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults.

According to IMS sales data, Symbyax had annual sales of approximately $82m in the US.

Teva is a global pharmaceutical company with a focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas as well as biologics.